Key Development
Ichnos Glenmark Innovation, Inc. (IGI), a global clinical-stage biotechnology company, submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for ISB 2301.
Product Details
ISB 2301 is a first-in-class, investigational multispecific immune cell activator designed to target three tumor-associated antigens (TAAs) and engage both T cells and natural killer (NK) cells. The pentaspecific molecule combines five binding specificities: three tumor-associated antigens plus T-cell and NK-cell activation.
Technology Platform
The drug candidate was engineered using IGI's proprietary BEAT® Multispecific Platform and is designed to recognize three tumor-associated antigens while engaging both T cells and NK cells through complementary mechanisms including antibody-dependent cellular cytotoxicity (ADCC), checkpoint inhibition, and the induction of a sustained type 1 immune response.
Clinical Development Plan
IGI plans to initiate a Phase 1 clinical trial evaluating ISB 2301 in patients with solid tumors in 2027. The trial will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity in patients with advanced solid tumors.
Preclinical Results
In preclinical studies, ISB 2301 demonstrated favorable pharmacokinetic and tolerability profiles in non-human primates, supporting the planned clinical evaluation.
Management Commentary
Lida Pacaud, M.D., President and Chief Executive Officer of IGI, stated: "Submission of the IND for ISB 2301 marks an important milestone in advancing IGI's multispecific oncology pipeline into clinical development. This pentaspecific candidate is designed to integrate multiple tumor-targeting and immune-engaging functions within a single molecule. Our preclinical results have demonstrated a compelling anti-cancer profile for ISB 2301, a candidate we believe to be highly differentiated from current approaches."
Company Background
IGI is a global, fully integrated clinical-stage biotechnology company focused on developing innovative biologics in oncology, headquartered in New York, NY. The company is advancing a pipeline of novel, first-in-class Multispecifics™ powered by its proprietary BEAT® technology platform.
Financial Impact
Financial impact not quantified in the disclosure.